GlassScriptPhysician profile
Halim Bou Daher
NPI 1801473061
$1,235.67
in general payments reported to CMS, 2019-2025
8 companies · $620 in 2025
The $620 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.83 · 2024: $578 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.67 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $363.13 | 2024-2025 | |
| Janssen Biotech, INC. | $289.69 | 2024-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $203.71 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $133.82 | 2024 | Livdelzi |
| Ardelyx, INC. | $122.09 | 2024 | Ibsrela |
| Abbvie INC. | $85.40 | 2025 | Mavyret, Linzess |
| Mallinckrodt Hospital Products INC. | $19.11 | 2023 | Terlivaz |
| Ascendis Pharma Endocrinology INC | $18.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halim Bou Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.